Literature DB >> 7765452

Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering.

A Bardelli1, C Ponzetto, P M Comoglio.   

Abstract

Hepatocyte growth factor/scatter factor (HGF/SF) is a heparin-binding polypeptide which shares structural domains with enzymes of the blood clotting cascade. HGF/SF is secreted by cells of mesodermal origin and has powerful mitogenic, motogenic and morphogenic activity on epithelial and endothelial cells. HGF/SF is produced as a biologically inactive single-chain precursor (pro-HGF/SF) most of which is sequestered on the cell surface or bound to the extracellular matrix. Maturation into the active alpha beta heterodimer results from proteolytic cleavage by a urokinase-type protease, which acts as a pro-HGF/SF convertase. The primary determinant for receptor binding appears to be located within the alpha-chain. The interaction of the alpha-chain with the receptor is sufficient for the activation of the signal cascade involved in the motility response. However, the complete HGF/SF protein seems to be required to elicit a mitogenic response. HGF/SF binds with high affinity to a transmembrane receptor, p190MET, encoded by the MET proto-oncogene. p190MET is the prototype of a distinct subfamily of heterodimeric tyrosine kinases, including the putative receptors Ron and Sea. The mature form of p190MET is a heterodimer of two disulfide-linked subunits (alpha and beta). The alpha-subunit is extracellular and heavily glycosylated. The beta-subunit consists of an extracellular portion involved in ligand binding, a membrane spanning segment, and a cytoplasmic tyrosine kinase domain. Both subunits derive from glycosylation and proteolytic cleavage of a common precursor of 170 kDa. In polarized epithelial cells the HGF/SF receptor is selectively exposed in the basolateral plasmalemma, where it is associated with detergent-insoluble components. Two Met isoforms, carrying an intact ligand binding domain but lacking the kinase domain due to truncation of the beta-subunit, arise from alternative post-transcriptional processing of the mature form. One truncated form is soluble and released from the cells. HGF/SF binding triggers tyrosine autophosphorylation of the receptor beta-subunit. Autophosphorylation on the major phosphorylation site Y1235 upregulates the kinase activity of the receptor, increasing the Vmax of the phosphotransfer reaction. Negative regulation of the kinase activity occurs through phosphorylation of a unique serine residue (S985) located in the juxtamembrane domain of the receptor. This phosphorylation is triggered by two distinct pathways involving either protein kinase C activation or increase in intracellular Ca2+ concentration. Upon ligand binding, the HGF/SF receptor recruits and activates several cytoplasmic effectors, including phosphatidylinositol 3-kinase (PI 3-K), phospholipase C-gamma (PLC-gamma), pp60c-Src, a tyrosine phosphatase, and a Ras-guanine nucleotide exchanger.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7765452     DOI: 10.1016/0168-1656(94)90002-7

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  14 in total

1.  Biological effects of targeted inactivation of hepatocyte growth factor-like protein in mice.

Authors:  J A Bezerra; T L Carrick; J L Degen; D Witte; S J Degen
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

2.  c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death.

Authors:  Rong Bu; Shahab Uddin; Maqbool Ahmed; Azhar R Hussain; Saif Alsobhi; Tarek Amin; Abdurahman Al-Nuaim; Fouad Al-Dayel; Jehad Abubaker; Prashant Bavi; Khawla S Al-Kuraya
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

Review 3.  Hepatocyte growth factor/scatter factor-induced intracellular signalling.

Authors:  K A Stuart; S M Riordan; S Lidder; L Crostella; R Williams; G G Skouteris
Journal:  Int J Exp Pathol       Date:  2000-02       Impact factor: 1.925

4.  STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family.

Authors:  A Iwama; N Yamaguchi; T Suda
Journal:  EMBO J       Date:  1996-11-01       Impact factor: 11.598

5.  Role of c-Met in cancer: emphasis on lung cancer.

Authors:  Ravi Salgia
Journal:  Semin Oncol       Date:  2009-04       Impact factor: 4.929

Review 6.  The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.

Authors:  Weon-Kyoo You; Donald M McDonald
Journal:  BMB Rep       Date:  2008-12-31       Impact factor: 4.778

7.  Characterization of the enhancing effect of protamine on the proliferative activity of hepatocyte growth factor in rat hepatocytes.

Authors:  Ke-Xin Liu; Yukio Kato; Kunio Matsumoto; Toshikazu Nakamura; Taiichi Kaku; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2009-01-06       Impact factor: 4.200

8.  Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction.

Authors:  Monika Kwiecinski; Andrea Noetel; Natalia Elfimova; Jonel Trebicka; Stephanie Schievenbusch; Ingo Strack; Levente Molnar; Melanie von Brandenstein; Ulrich Töx; Roswitha Nischt; Oliver Coutelle; Hans Peter Dienes; Margarete Odenthal
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

9.  Activating mutation in MET oncogene in familial colorectal cancer.

Authors:  Deborah W Neklason; Michelle W Done; Nykole R Sargent; Ann G Schwartz; Hoda Anton-Culver; Constance A Griffin; Dennis J Ahnen; Joellen M Schildkraut; Gail E Tomlinson; Louise C Strong; Alexander R Miller; Jill E Stopfer; Randall W Burt
Journal:  BMC Cancer       Date:  2011-10-04       Impact factor: 4.430

10.  Non-autocrine, constitutive activation of Met in human anaplastic thyroid carcinoma cells in culture.

Authors:  J D Bergström; A Hermansson; T Diaz de Ståhl; N E Heldin
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.